Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma
Sponsor: Gilead Sciences
Listed as NCT00003338, this PHASE2/PHASE3 trial focuses on Lymphoma and remains ongoing. Sponsored by Gilead Sciences, it has been updated 7 times since 1997, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status PHASE2_PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Mar 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .